Scholarlink

Background <p>Fatigue significantly affects health-related quality of life (HRQoL) in patients with immune thrombocytopenia (ITP). However, the interplay between fatigue and cytokines in ITP remains poorly understood.</p> Methods <p>This study included 100 patients with persistent or chronic ITP who had not received ITP-directed therapy in the previous 8&#xa0;weeks and 50 age-matched healthy controls. Fatigue and HRQoL were assessed using the Functional Assessment of the Chronic Illness Therapy (FACIT) scale. Concurrently, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, IL-17, and interferon-gamma (IFN-γ) were measured via enzyme-linked immunosorbent assay (ELISA).</p> Results <p>ITP patients had significantly lower total FACIT scores [median 146 (range 59–160]) and fatigue subscale scores [median 45 (range 9–52]) than controls [155 (149–159) and 49 (44–52), respectively; both <i>p</i> &lt; 0.001]. IL-12 levels were significantly elevated in patients (313.2 vs. 95.5&#xa0;pg/mL; <i>p</i> &lt; 0.001) and showed a significant negative correlation with FACIT scores (Spearman’s ρ = –0.272, <i>p</i> = 0.007). Multivariate analysis revealed that female sex, longer disease duration among patients with chronic ITP (&gt; 24&#xa0;months), and elevated IL-12 levels were independently associated with greater fatigue and poorer HRQoL.</p> Conclusions <p>ITP is associated with significant fatigue and HRQoL impairment, with IL-12 emerging as a potential immunological marker linked to this symptom burden.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Plasma interleukin-12 levels as a potential biomarker of fatigue and quality of life in patients with primary immune thrombocytopenia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月4日

查看全文
  • Sarthak Wadhera,
  • Arihant Jain,
  • Aarushi Sahni,
  • Rudra Narayan Swain,
  • Charanpreet Singh,
  • Aditya Jandial,
  • Ritu Aggarwal,
  • Rekha Hans,
  • Gaurav Prakash,
  • Alka Khadwal,
  • Sandeep Grover,
  • Reena Das,
  • Pankaj Malhotra

摘要

Background

Fatigue significantly affects health-related quality of life (HRQoL) in patients with immune thrombocytopenia (ITP). However, the interplay between fatigue and cytokines in ITP remains poorly understood.

Methods

This study included 100 patients with persistent or chronic ITP who had not received ITP-directed therapy in the previous 8 weeks and 50 age-matched healthy controls. Fatigue and HRQoL were assessed using the Functional Assessment of the Chronic Illness Therapy (FACIT) scale. Concurrently, plasma levels of interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12, IL-17, and interferon-gamma (IFN-γ) were measured via enzyme-linked immunosorbent assay (ELISA).

Results

ITP patients had significantly lower total FACIT scores [median 146 (range 59–160]) and fatigue subscale scores [median 45 (range 9–52]) than controls [155 (149–159) and 49 (44–52), respectively; both p < 0.001]. IL-12 levels were significantly elevated in patients (313.2 vs. 95.5 pg/mL; p < 0.001) and showed a significant negative correlation with FACIT scores (Spearman’s ρ = –0.272, p = 0.007). Multivariate analysis revealed that female sex, longer disease duration among patients with chronic ITP (> 24 months), and elevated IL-12 levels were independently associated with greater fatigue and poorer HRQoL.

Conclusions

ITP is associated with significant fatigue and HRQoL impairment, with IL-12 emerging as a potential immunological marker linked to this symptom burden.